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Abstract 
Objective: As depressive disorders are highly heterogeneous, and as patients exhibit 
wide differences in clinical characteristics and comorbidities, we aim to examine 
whether and how demographic and clinical correlates affect healthcare costs for 
patients with depression in a real-world setting. 
Method: A national cohort of adult patients (n=216,557) who received treatment for 
depression was identified from the National Health Insurance Research Database in 
Taiwan. Factors associated with service use and healthcare costs over a 12-month 
period were explored, with a particular focus on past treatment history, comorbid 
physical illnesses, painful physical symptoms, and choice of initial antidepressants.  
Results: Depression severity, past treatment history, comorbid mental/physical 
illnesses, painful physical symptoms, and choice of initial antidepressants were found 
to be associated with healthcare costs in the following year, although the nature of the 
associations differed across cost categories. The presence of comorbid cardiovascular 
disease or certain painful physical symptoms at baseline was associated not only with 
higher non-psychiatric but also with higher psychiatric costs; moreover, patients with 
these comorbidities were shown to have increased use of psychiatric emergency and 
inpatient services.  
Conclusion: Healthcare costs for depression are affected by a number of clinical 
characteristics and comorbidities of patients. The importance of comorbid pain and 
cardiovascular conditions warrants further research. 
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1. Introduction  
 Unipolar depressive disorder was the fourth leading cause of disease burden 
among all diseases in 2002 (Mathers and Loncar, 2006) and is predicted to become 
the leading cause in 2015 (WHO 2008). The total direct healthcare costs of depression 
in Taiwan, as in many other countries, rose by 50% over the period of 2000-2002 
(Chan et al., 2006); the prevalence of antidepressant use also doubled from 1997 to 
2004 (Chien et al., 2007). This could imply an increase in the need for depression 
treatment, a reduction in the treatment gap, or over-provision of care. Given the 
anticipated rise in the future healthcare costs for patients with depression, it would 
help inform decision-making to assess the impact of depression treatment from an 
economic perspective.  
Depressive disorders comprise a group of heterogeneous conditions. The extent 
to which treatment history, comorbidities of physical/mental illnesses, and choice of 
antidepressants can influence healthcare costs remains to be determined. Depression 
is known to be associated with a variety of physical conditions (Katon 2003) of whom 
cardiovascular diseases (CVD) and painful physical symptoms (PPS) warrant further 
investigation. Depression and CVD are projected to be the first and second leading 
causes of health-related burden in 2015 (WHO 2008), and there is accumulating 
evidence suggesting close interrelationships between these highly-prevalent 
conditions (Sorensenf et al., 2005; Thombs et al., 2006): for instance, depressive 
symptoms have been found to be a risk factor for cardiac events in patients with 
coronary heart disease (Barth et al., 2004; van Melle et al., 2004). To assess the 
economic impact of treatment for depression, PPS should also be carefully considered. 
Previous studies have revealed high prevalence of pain complaints in depressed 
patients (Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003) and 
outcomes of treatment for depression may be poorer in the presence of PPS (Fava et 
al., 2004; Gameroff and Olfson, 2006; Leuchter et al., 2010). Furthermore, individual 
antidepressants have been shown to have a wide range of cardiovascular effects 
(Taylor 2008), and antidepressants may differ in the effectiveness for the relief of PPS. 
Therefore, the presence of these co-occurring CVD and PPS may influence the choice 
of antidepressants and healthcare utilization, with potential impact on healthcare 
costs. 
The current study, conducted in a real-world setting, seeks to measure healthcare 
costs for people with depression using claims data from the National Health Insurance 
Research Database (NHIRD) in Taiwan. The objective of this study is to identify 
which demographic and clinical characteristics and comorbidities are associated with 
total healthcare costs, as well as costs for specific groups of services, with a particular 
focus on comorbid pain and cardiovascular diseases. 
 
2. Materials and methods  
 
2.1. Data 
Taiwan is a country with a population of around 23,000,000. The GDP per capita 
in 2003/2004 was 13,773/15,012 US dollars. National Health Insurance (NHI) in 
Taiwan is a single-payer compulsory social insurance plan that centralizes the 
disbursement of healthcare funds and guarantees equal access to health care for all 
citizens. In 2003, there were 21,869,478 individuals enrolled in the NHI with a 
coverage rate of 96%. The NHI contracted 17,022 medical institutions, which 
constituted 93.8% of medical institutions nationwide. By the end of 2005, 
approximately 22.7 million individuals had been enrolled in Taiwan’s NHI program 
 3 
with a coverage rate of 98%. The NHI system in Taiwan contains the NHIRD which 
consists of data characterizing healthcare utilization of insured residents, including 
expenditures, medical procedures/treatments, and basic characteristics of patients, 
providers and physicians. The NHIRD uses the International Classification of 
Diseases, 9th revision, clinical modification diagnoses (ICD-9-CM). 
In this study, the included subjects were identified from the NHIRD. The index 
date was defined as the date on which the subject was first prescribed an 
antidepressant for a diagnosis of depressive disorder in 2003. Data on all NHI 
information for each subject were extracted for the two-year period spanning the 
index date (one year preceding, and one year following). 
 
2.2. Participants 
 All subjects in NHIRD meeting the following criteria were included: 
 At least one prescription for an antidepressant for treatment of major depressive 
disorder (MDD) (ICD-9-CM codes: 296.2x, 296.3x) or minor depression 
(ICD-9-CM codes: 311.xx, 300.4x) in 2003.  
 Data available for a minimum of 12 months before and after the index date. 
 Age 18 years or over on the index date. 
A subsample of patients with newly-diagnosed depression was also identified within 
this overall sample, which was operationally defined as individuals who were free of 
antidepressant use or a depression diagnosis for a minimum of 12 months before the 
index date. 
 
2.3. Demographic and clinical information 
 Demographic and clinical data were extracted, including age, gender, diagnosis 
of depressive disorders, and initial choice of antidepressants on the index date. 
Participants were further grouped according to past treatment history, i.e., 
newly-diagnosed depression and non-newly-diagnosed depression. 
 Baseline characteristics were traced back for all subjects for the 12 months prior 
to the index date, including comorbid mental disorders, physical illnesses (CVD, 
diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), renal 
diseases, and cancer), PPS (backache, headache, musculoskeletal and gastrointestinal 
pain), and healthcare utilization/expenditure. 
 
2.4. Service use and costs 
Service use components extracted from the NHIRD included outpatient services, 
emergency attendances, and inpatient stays. Service use over the 12-month study 
period was described by the percentage of patients with at least one unit of service use 
and the mean number of service contacts for the whole sample. Medication use 
regarding prescriptions of antidepressants was identified. All costs over the 12-month 
study period were calculated from the actual claims data, were described by service 
categories, and expressed in 2003-4 US dollars.  
 
2.5. Data analysis 
Sociodemographic data, clinical characteristics, baseline healthcare 
utilization/expenditure, and initial antidepressant treatment were described for the 
overall sample and compared between newly-diagnosed depression and 
non-newly-diagnosed depression groups.  
To identify characteristics predictive of healthcare costs over the 12-month 
period, a multivariate generalized linear regression model with a log link and gamma 
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variance function was employed (McCullagh and Nelder, 1989). Separate models 
were run for total healthcare costs, psychiatric costs, and non-psychiatric costs. And to 
measure the model fit, the root mean square error (RMSE) (Zheng and Agresti, 2000) 
for each model was computed after excluding 0.1% of subjects with extremely large 
predicted values in costs. The independent variables considered in these models were 
age, sex, index depression diagnosis, past treatment history, initial choice of 
antidepressants, baseline comorbid mental/physical disorders, baseline PPS, and 
baseline total healthcare expenditure. These variables were first selected using a 
univariate model and those significant at the 5% level were included subsequently. A 
backward selection process was then applied to obtain the final multivariate model, 
using a 5% level of significance. Subsequently, such analyses were performed in a 
subsample of subjects with newly-diagnosed depression as they were a group which 
warrants further investigation. This was also to determine the influence of past 
treatment history on the findings from the overall sample.  
As use of psychiatric emergency and/or inpatient services may be indicators for 
patients who require more intensive care, thus generating higher costs, we examined 
variations in use of these two key services in further analyses. With use of psychiatric 
emergency services and use of psychiatric inpatient services as dependent variables, 
independent variables were entered in a multivariate logistic regression with a 
forward LR (likelihood ratios) method to explore predictors of use over the 12-month 
study period. A p-value of 0.05 was considered significant for all statistical analyses, 
which were performed using SPSS version 17.0 (Chicago, IL, USA).  
 
3. Results 
 A total of 216,557 adult individuals met the inclusion criteria, including a 
subsample of 84,577 persons with newly-diagnosed depression. Table 1 shows that for 
the overall sample, 61.9% were females and 18.7% were aged 65 years or over on the 
index date. Regarding baseline comorbidities, 26.9% had CVD, 10.9% had DM, and 
15.2% had COPD. Comorbid PPS rates were particularly high for both the overall 
sample and the subsample of individuals with newly-diagnosed depression. At the 
index visit, 45.6% of the overall sample were prescribed selective serotonin reuptake 
inhibitors (SSRIs) and 8.6% prescribed serotonin norepinephrine reuptake inhibitors 
(SNRIs). Only 3.1% of patients received other newer antidepressants (bupropion and 
mirtazapine).  
 Patients with newly-diagnosed depression were younger and had a greater 
proportion of females compared to those with non-newly-diagnosed depression. They 
had lower rates of comorbid physical/mental illnesses and lower prevalence of PPS. 
Health service utilization at baseline was lower as well. A higher proportion of them 
were prescribed newer generation antidepressants. 
 
3.1. Service use and costs 
 Service use data are summarized in Table 2. Of the overall sample, 85.1% had 
used psychiatric outpatient services over the 12-month study period. Over the same 
period, 5.0% of them had been admitted to psychiatric wards for inpatient treatment 
and 1.6% had psychiatric emergency attendances. 
 Costs of outpatient contacts in total accounted for 63.6% of total healthcare costs 
for these patients. And overall expenditures on psychiatric services were around 
29.2% of the total healthcare costs. 
 
3.2. Total healthcare costs 
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 Table 3 reveals that higher total healthcare costs were associated with older age, 
male gender, an index diagnosis of MDD, non-newly-diagnosed depression, and 
having CVD, DM, COPD, renal disease, cancer or PPS at baseline.  
 Use of SNRIs, other newer generation antidepressants and use of multiple 
antidepressants were related to higher costs compared to use of SSRIs at the index 
date. Lower costs were observed for those using tricyclic antidepressants (TCAs), 
flupentixol/melitracen, and other older antidepressants (maprotiline, moclobemide, 
and trazodone). The analysis on the subsample of newly-diagnosed depression 
revealed similar results with those from the full sample. Regarding the model fit, 
RMSE of the model for total costs was 1316. The predicted mean of total costs was 
1925 US dollars versus the actual mean costs 1731 US dollars. 
 
3.3. Non-psychiatric healthcare costs 
 Older age, and male gender were related to higher non-psychiatric costs in the 
following year (Table 4). Compared to patients with history of either an 
antidepressant treatment or a depression diagnosis, those with newly-diagnosed 
depression had higher non-psychiatric costs. Patients with an index diagnosis of MDD 
or a baseline comorbid mental disorder were associated with lower costs, with the 
only exceptions being alcohol, substance misuse, multiple drugs-related mental 
disorders and dementia. The presence of a comorbid physical illness or PPS at 
baseline was related to higher non-psychiatric costs.  
 Patients prescribed older antidepressants had higher non-psychiatric costs in the 
following year compared to those prescribed SSRIs while patients prescribed newer 
antidepressants such as SNRIs or bupropion/mirtazapine had non-psychiatric costs 
that did not differ significantly. The RMSE of the model was 4380. And the predicted 
mean of non-psychiatric costs was 1452 US dollars while the actual mean cost was 
1226 US dollars. 
 
3.4. Psychiatric healthcare costs  
 As shown in Table 4, male gender was associated with higher psychiatric costs in 
the following year. Not surprisingly, patients having an index diagnosis of MDD had 
increased costs as did those with baseline comorbid mental disorders. Patients with 
newly-diagnosed depression had lower psychiatric costs compared to those who had 
been diagnosed prior to the index date. Younger age was shown to be related to higher 
psychiatric costs. 
 Use of newer generation antidepressants or multiple antidepressants prescribed 
on the index date were related to higher psychiatric costs compared to those 
prescribed SSRIs, while use of older antidepressants was related to lower costs. 
Among comorbid physical illnesses, CVD was the only one found to increase 
psychiatric costs. And among PPS, only pain complaints relating to the central 
nervous system (CNS), i.e., headache/dizziness/or migraine, were related to higher 
psychiatric costs. The RMSE of the model was 1074. The predicted mean of 
psychiatric costs was 577 US dollars and the actual mean was 506 US dollars. 
 
3.5. Use of psychiatric emergency and inpatient services 
 Younger age, male gender, a diagnosis of MDD or certain comorbid mental 
disorders were more likely to lead to psychiatric emergency attendances and 
hospitalizations (Table 5). CVD or COPD was related to higher odds of using 
psychiatric emergency and hospitalization services. Headache/dizziness/or migraine 
complaints at baseline were associated with an increase in the odds of using 
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psychiatric emergency and hospitalization services as well.    
 
4. Discussion 
 This study provided new evidence on the associations between comorbidities, 
service use, and healthcare costs for patients with depression. Although the nature of 
the associations differed across cost categories, the multivariate models revealed that 
age, gender, depression severity, past treatment history, comorbid mental/physical 
illnesses, PPS, and choice of initial antidepressants were all associated with healthcare 
costs in the following year. Factors including comorbid CVD and PPS were further 
explored to understand patterns of variation in psychiatric emergency and inpatient 
service use over the 12-month study period.  
  
4.1. Demographic characteristics 
 Although previous studies have suggested that medical costs are higher for 
women than men (Owens 2008; Woolhandler and Himmelstein, 2007), this study 
found a different result: for patients with depressive disorders, and taking into account 
other influences on costs, male gender was shown to be associated with higher costs 
for both non-psychiatric and psychiatric healthcare services. 
 There have been few recent studies that specifically examined the association 
between gender and healthcare utilization/expenditure for patients with depressive 
disorders. A study of elderly patients with psychiatric diagnoses suggested that men 
had more emergency attendances and had greater inpatient costs than women, which 
led some investigators to propose that when men eschew regular visits to physicians, 
it is likely that emergency or inpatient treatment may be required as illness progresses 
(Husaini et al., 2002). Consistently, male patients were shown to be associated with 
increased use of psychiatric emergency and inpatient services in the current study. 
One interpretation of our results is therefore that male patients with depression may 
enter the healthcare system later in the disease course, by which time their illness is 
more severe, thus generating higher costs.  
 
4.2. Comorbid cardiovascular disease 
Among the frequently co-occurring physical illnesses considered in this study, 
CVD was the only one shown to increase not only non-psychiatric but also psychiatric 
costs. Depression has been revealed to be an independent risk factor for the future 
onset, progression, and recurrence of CVD (Carney et al., 1988; Ferketich et al., 2000; 
Nicholson et al., 2006; Rugulies 2002; Sesso et al., 1998; Wassertheil-Smoller et al., 
2004), which can be mediated both by poor health behavior and by the 
pathophysiological correlates of depressive symptoms, e.g., neuroendocrine and 
inflammatory activation (Frasure-Smith and Lesperance, 2010; Rozanski et al., 2005). 
Additionally, individual antidepressants have a wide range of cardiovascular effects 
which may affect cardiovascular-related morbidity and mortality (Coupland et al., 
1997; Taylor 2008; Vieweg and Wood, 2004); it seems likely that the co-existence of 
CVD and depression may impact patients' physical conditions and their 
non-psychiatric costs.  
As well, we found that the presence of comorbid CVD was related to higher odds 
of using both psychiatric emergency and hospitalization services which was consistent 
with the finding of increased psychiatric costs in these patients. CVD has been shown 
to be correlated with certain lifestyles, alcohol consumption, and personality traits 
(e.g., Type D personality), some of which seem to be highly correlated with use of 
psychiatric services. For instance, Type D has been conceptualized as a personality 
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trait comprising negative affectivity and social inhibition that often co-occurs with 
depression in patients with coronary artery disease, and that may inhibit remission of 
depressive symptoms (Albus et al., 2011; Denollet et al., 2010). Although it can only 
be speculative, the identified association between the presence of CVD and increased 
psychiatric service utilization/expenditure in this study may be understood as being 
indirectly influenced by these unmeasured and potentially associated factors.   
 
4.3. Painful physical symptoms 
 The relationships between depression and pain are complex with similar brain 
areas regulating both mood and the affective components of pain (Giesecke et al., 
2005). High prevalence of pain complaints has been reported in patients with 
depression (Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003). Our 
results added to this evidence in finding a high percentage of comorbid PPS in 
patients with newly-diagnosed depression, which supports findings from previous 
studies that pain usually appears before the development of MDD (Ohayon and 
Schatzberg, 2010). On the other hand, increasing pain interference has been reported 
to be associated not only with higher odds of having depressive disorders (Barry et al., 
2012), but also with adverse impact on poor treatment response (Bair et al., 2004). 
Pain complaints seem to be characteristic of depression that is more severe and 
refractory to antidepressant treatments, as evidenced by higher healthcare utilization, 
and higher costs (Gameroff and Olfson, 2006).  
 As most previous studies were based on highly selective samples and did not 
consider many comorbidities, it is unclear whether these results could be generalized 
to larger samples of patients in a real-world setting, and to what extent other factors 
such as comorbid mental/physical illnesses would contribute to the possible 
association between PPS, healthcare utilization, and treatment outcome. In the current 
study, we concurred with previous studies in suggesting that the presence of PPS was 
associated with higher total healthcare costs in the following year; this remained true 
for those with newly-diagnosed depression. In addition, analyses based on origins of 
pain complaints found that the co-existence of PPS was generally associated with 
higher non-psychiatric costs but lower psychiatric costs, with headache being the only 
exception: unlike pain complaints over other somatic systems, having headache was 
associated with higher psychiatric costs and greater odds of using psychiatric 
emergency and inpatient services. A recent study suggested the existence of 
differences in separate pain modalities in relation to depression, and that a closer 
relationship may exist between MDD and neuropathic pain than non-neuropathic pain 
(Ohayon and Stingl, 2012). It seems possible that a more direct relationship might 
exist between depression and pain complaints over the central nervous system than 
PPS from other somatic systems as our data might suggest. 
 
4.4. Antidepressant choice 
The current study showed that initial choice of antidepressants appears to be 
associated with total healthcare costs in the following year. Compared to patients 
prescribed SSRIs, those prescribed older antidepressants had lower total and 
psychiatric costs, whilst patients prescribed SNRIs, and other newer antidepressants 
had higher total and psychiatric costs. However, to a large extent these differences 
may be attributed to physician selection: patients prescribed older antidepressants 
were more likely to suffer minor depression, to be older, and to have more PPS and 
physical comorbidities at baseline. Contrarily, patients prescribed newer 
antidepressants were more likely to have MDD, to be younger, and to have fewer 
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baseline physical comorbidities (not shown in this paper). These distinctive 
characteristics suggest the existence of physician selection based on patients' clinical 
characteristics that unfortunately could not be fully accounted for by the adjustment 
factors in our analyses. 
Further support could be drawn from the comparisons between cost models: as 
seen in Table 4, patients prescribed SNRIs and other newer antidepressants were 
similar to those prescribed SSRIs in non-psychiatric costs, whilst patients prescribed 
TCAs and other older antidepressants generally had higher non-psychiatric costs. 
These results could be interpreted as showing that there were differences especially in 
physical comorbidities between these two groups of depressed patients. Previous 
database analyses have also suggested that SSRI users may have higher 
depression-related service expenditures but lower non-depression-related service 
expenditures than TCA users (Pan et al., 2012). Along with these previous findings, 
our results suggest that depressed patients prescribed older antidepressants may be 
different from those prescribed SSRIs, SNRIs, and other newer antidepressants in 
terms of clinical features of depression and comorbidities. 
 
4.5. Limitations and conclusions 
 As service use data contained in the NHIRD includes only health services 
provided by the NHI system in Taiwan, the perspective of the current analysis was 
relatively limited, and we were not able to analyze wider economic impacts. 
Confounding or selection bias due to the nonrandomized study design should be borne 
in mind while interpreting the results, although the real-world context and 
whole-country coverage are strengths, especially when analyzing the inherent 
heterogeneity of clinical presentations and patient characteristics and their influences 
on help-seeking behaviors, clinical outcomes, and costs.  
In conclusion, the current study—based on a large national database—suggests a 
set of significant correlates of healthcare costs for depressed patients. Male gender 
and a diagnosis of MDD were significantly associated with higher total healthcare 
costs. The baseline comorbidities of CVD and headache were associated not only with 
higher non-psychiatric but also with higher psychiatric costs; moreover, these 
comorbidities were related to increased use of psychiatric emergency and inpatient 
services in the following year. 
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Table 1. Sociodemographic and clinical characteristics of the overall sample and comparisons between newly-diagnosed and non-newly-diagnosed 
depression* 
 The overall sample 
(n=216,557) 
Newly-diagnosed 
depression 
(n=84,577) 
Non-newly-diagnosed 
depression 
(n=131,980) 
Age [mean (SD)] 
Age categories [n (%)] 
   >=85 
   75-84 
   65-74 
   55-64 
   45-54 
   35-44 
   25-34 
   18-24 
47.4 (17.0) 
 
1756 (0.8) 
13626 (6.3) 
25019 (11.6) 
27438 (12.7) 
44252 (20.4) 
46692 (21.6) 
36338 (16.8) 
21436 (9.9) 
43.9 (17.0) 
 
637 (0.8) 
4058 (4.8) 
7267 (8.6) 
8787 (10.4) 
15520 (18.4) 
18115 (21.4) 
17740 (21.0) 
12453 (14.7) 
49.7 (16.6) 
 
1119 (0.8) 
9568 (7.2) 
17752 (13.5) 
18651 (14.1) 
28732 (21.8) 
28577 (21.7) 
18598 (14.1) 
8983 (6.8) 
Sex [n (%)] 
   Male 
   Female 
 
82,414 (38.1) 
134,143 (61.9) 
 
30683 (36.3) 
53894 (63.7) 
 
51731 (39.2) 
80249 (60.8) 
Depression diagnosis at index visit [n (%)] 
   Major depression 
   Minor depression 
 
 
78296 (36.2) 
 
 
27029 (32.0) 
 
 
51267 (38.8) 
Formatted: Left:  2.54 cm, Right: 
2.54 cm, Top:  3.17 cm, Bottom: 
3.17 cm, Width:  29.7 cm, Height: 
21 cm
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138261 (63.8) 57548 (68.0) 80713 (61.2) 
Baseline physical illnesses [n (%)] 
  Cardiovascular  disease 
  Diabetes mellitus 
  Chronic obstructive pulmonary disease 
  Hyperlipidemia 
  Hypertension 
  Renal disease 
  Cancer  
 
58350 (26.9) 
23563 (10.9) 
32898 (15.2) 
23249 (10.7) 
51271 (23.7) 
11854 (5.5) 
8864 (4.1) 
 
18132 (21.4) 
7198 (8.5) 
10886 (12.9) 
7351 (8.7) 
15596 (18.4) 
3766 (4.5) 
2850 (3.4) 
 
40218 (30.5) 
16365 (12.4) 
22012 (16.7) 
15898 (12.0) 
35675 (27.0) 
8088 (6.1) 
6014 (4.6) 
Baseline painful physical symptoms [n 
(%)] 
   Musculoskeletal 
   Back 
   Gastrointestinal 
   Headache/migraine/dizziness 
 
 
99,455 (45.9) 
69,981 (32.3) 
111,271 (51.4) 
88,164 (40.7) 
 
 
36168 (42.8) 
25036 (29.6) 
40018 (47.3) 
29996 (35.5) 
 
 
63287 (48.0) 
44945 (34.1) 
71253 (54.0) 
58168 (44.1) 
Baseline mental illnesses [n (%)] 
   Schizophrenia 
   Other psychotic disorder 
   Substance related 
   Alcohol related 
   Drugs related 
   Bipolar spectrum disorder 
   Dementia 
 
8207 (3.8) 
4650 (2.1) 
6127 (2.8) 
1748 (0.8) 
1084 (0.5) 
3882 (1.8) 
7356 (3.4) 
 
1538 (1.8) 
775 (0.9) 
1081 (1.3) 
254 (0.3) 
196 (0.2) 
457 (0.5) 
1426 (1.7) 
 
6669 (5.1) 
3875 (2.9) 
5046 (3.8) 
1494 (1.1) 
888 (0.7) 
3425 (2.6) 
5930 (4.5) 
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   Generalized anxiety disorder 
   Obsessive-compulsive disorder 
   Panic disorder 
   Phobic disorder 
   Post-traumatic stress disorder 
   Sleep disorder 
   Hyperkinetic syndrome   
11718 (5.4) 
3797 (1.8) 
7388 (3.4) 
1742 (0.8) 
404 (0.2) 
52001 (24.0) 
133 (0.1) 
2313 (2.7) 
180 (0.2) 
588 (0.7) 
131 (0.2) 
20 (0.0) 
15196 (18.0) 
22 (0.0) 
9405 (7.1) 
3617 (2.7) 
6800 (5.2) 
1611 (1.2) 
384 (0.3) 
36805 (27.9) 
111 (0.1) 
Baseline healthcare service use  
   Number of outpatient visits [mean 
(SD)] 
   ER visit [n (%)] 
   Hospitalization [n (%)] 
 
31.6 (24.8) 
74970 (34.6) 
45397 (21.0) 
 
23.9 (20.9) 
26178 (31.0) 
13576 (16.1) 
 
36.5 (25.8) 
48792 (37.0) 
31821 (24.1) 
Total 12-month costs prior to index date 
[mean (SD)] 
 
1365.6 (2397.2) 
 
894.6 (2089.0) 
 
1667.5 (2529.6) 
Index AD [n (%)] 
  SSRI 
  SNRI 
  Other newer AD 
  TCA 
  Flupentixol/melitracen 
  Other older AD 
  Multiple AD 
 
98791 (45.6) 
18520 (8.6) 
6759 (3.1) 
18787 (8.7) 
11449 (5.3) 
40897 (18.9) 
21354 (9.9) 
 
42476 (50.2) 
7549 (8.9) 
3104 (3.7) 
5873 (6.9) 
4341 (5.1) 
14016 (16.6) 
7218 (8.5) 
 
56315 (42.7) 
10971 (8.3) 
3655 (2.8) 
12914 (9.8) 
7108 (5.4) 
26881 (20.4) 
14136 (10.7) 
Baseline characteristics were measured over the 12-month pre-index period. 
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Costs were expressed in 2003-4 US dollars. 
SD=standard deviation; AD=antidepressant; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin norepinephrine reuptake inhibitor; TCA=tricyclic 
antidepressant; other newer AD: bupropion and mirtazapine; other older AD: maprotiline, moclobemide, and trazodone. 
*All comparisons between newly-diagnosed and non-newly-diagnosed depression were statistically significant with a p< 0.001 (chi-squared test was used for 
categorical variables and independent t-test for continuous variables). 
 
Table 2. Service use and healthcare costs over the 12-month study period, overall sample 
Service use 
 n (% using) mean (SD)  
 
Psychiatric outpatient 
Psychiatric inpatient  
Psychiatric emergency      
Non-psychiatric outpatient 
Non-psychiatric inpatient 
Non-psychiatric emergency 
 
184271 (85.1) 
10916 (5.0) 
3515 (1.6) 
212327 (98.0) 
39077 (18.0) 
70812 (32.7) 
 
7.30 (7.72)  
0.08 (0.46)  
0.03 (0.42)  
27.48 (25.51) 
0.33 (0.98)  
0.76 (3.13)  
Healthcare costs ($, year 2003-4 values) 
 mean (SD)  
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Psychiatric outpatient 
Psychiatric inpatient 
Psychiatric emergency     
Non-psychiatric outpatient  
Non-psychiatric inpatient 
Non-psychiatric emergency   
Total 
356.64 (465.87)  
148.22 (992.87)  
0.86 (9.84)  
744.02 (1927.52)  
437.02 (2423.54) 
44.46 (171.97)  
1731.21 (3508.72)  
 
Table 3. Multivariate analysis (GLM) of total healthcare costs over the 12-month study period 
 RR (95% CI) 
 The overall sample 
(n=216,557) 
Newly-diagnosed depression 
(n=84,577) 
Age 1.011 (1.011, 1.011) 1.013 (1.013, 1.014) 
Sex 
Male 
 Female 
 
1.143 (1.134, 1.152) 
1 
 
1.231 (1.215, 1.247) 
1 
Depression diagnosis at index visit 
     Major depression 
     Minor depression      
 
1.134 (1.125, 1.143) 
1
 
1.160 (1.144, 1.176) 
1 
 18 
Past treatment history 
     Newly-diagnosed depression 
 
     Non-newly-diagnosed depression with history of 
both AD treatment and depression diagnosis 
 
     Non-newly-diagnosed depression with history of 
either AD treatment or depression diagnosis  
 
0.959 (0.952, 0.967) 
 
1.136 (1.121, 1.151) 
 
 
1 
 
-- 
 
-- 
 
 
-- 
Index AD treatment 
     SNRI 
     Other newer AD 
     TCA 
     Other older AD 
     Flupentixol/melitracen 
     Use of multiple ADs 
     SSRI 
 
1.160 (1.144, 1.176) 
1.142 (1.118, 1.166) 
0.905 (0.893, 0.918) 
0.956 (0.946, 0.965) 
0.876 (0.862, 0.891) 
1.177 (1.162, 1.192) 
1 
 
1.144 (1.118, 1.170) 
1.152 (1.114, 1.192) 
0.895 (0.872, 0.918) 
0.978 (0.960, 0.996) 
0.902 (0.876, 0.929) 
1.217 (1.189, 1.246) 
1 
Baseline physical illnesses 
  Cardiovascular disease 
     Yes vs. No 
  Diabetes mellitus 
      Yes vs. No 
  Chronic obstructive pulmonary disease 
      Yes vs. No 
 
 
1.180 (1.169, 1.191) 
 
1.256 (1.240, 1.271) 
 
1.122 (1.111, 1.134) 
 
 
1.270 (1.248, 1.293) 
 
1.315 (1.284, 1.347) 
 
1.126 (1.104, 1.148) 
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  Renal disease 
      Yes vs. No 
  Cancer 
      Yes vs. No  
 
1.161 (1.142, 1.181) 
 
1.326 (1.302, 1.351) 
 
1.230 (1.190, 1.270) 
 
1.478 (1.426, 1.532) 
Baseline painful physical symptoms 
   Musculoskeletal 
      Yes vs. No 
   Back 
      Yes vs. No 
   Gastrointestinal 
      Yes vs. No 
   Headache/migraine/dizziness 
      Yes vs. No 
 
 
1.068 (1.060, 1.077) 
 
1.062 (1.053, 1.071) 
 
1.067 (1.059, 1.075) 
 
1.049 (1.040, 1.057) 
 
 
1.069 (1.054, 1.084) 
 
1.069 (1.053, 1.085) 
 
1.059 (1.045, 1.073) 
 
1.046 (1.032, 1.061) 
Baseline mental illnesses 
   Schizophrenia 
      Yes vs. No 
   Other psychotic disorder 
      Yes vs. No 
   Substance related 
      Yes vs. No 
   Alcohol related 
      Yes vs. No 
   Drugs related 
 
 
1.890 (1.854, 1.927) 
 
1.185 (1.156, 1.215) 
 
1.301 (1.271, 1.331) 
 
1.484 (1.423, 1.548) 
 
 
 
2.456 (2.342, 2.575) 
 
1.368 (1.281, 1.461) 
 
1.323 (1.249, 1.401) 
 
1.662 (1.480, 1.867) 
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      Yes vs. No 
   Bipolar spectrum disorder 
      Yes vs. No    
   Dementia 
      Yes vs. No 
   Generalized anxiety disorder 
      Yes vs. No 
   Obsessive-compulsive disorder 
      Yes vs. No 
   Panic disorder 
      Yes vs. No 
   Post-traumatic stress disorder 
      Yes vs. No 
1.188 (1.128, 1.251) 
 
1.233 (1.199, 1.267) 
 
1.281 (1.255, 1.308) 
 
0.998 (0.982, 1.014) 
 
1.069 (1.039, 1.099) 
 
0.961 (0.941, 0.980) 
 
1.190 (1.094, 1.293) 
1.483 (1.301, 1.690) 
 
1.301 (1.194, 1.417) 
 
1.355 (1.289, 1.424) 
 
0.996 (0.958, 1.035) 
 
0.978 (0.854, 1.120) 
 
1.040 (0.964, 1.121) 
 
0.983 (0.655, 1.476) 
Total 12-month costs prior to index date (1000 USD) 1.182 (1.179, 1.185) 1.175 (1.170, 1.181) 
RR=relative risk; CI=confidence interval; AD=antidepressant; SNRI=serotonin norepinephrine reuptake inhibitor; TCA=tricyclic antidepressant; SSRI=selective 
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other older AD: maprotiline, moclobemide, and trazodone. 
 
Table 4. Multivariate analysis (GLM) of non-psychiatric costs and psychiatric costs over the 12-month study period, overall sample 
 RR (95% CI) 
 Non-psychiatric healthcare 
costs 
Psychiatric healthcare costs 
Age 1.019 (1.019, 1.020) 0.998 (0.997, 0.998) 
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Sex 
Male 
 Female 
 
1.073 (1.063, 1.082) 
1 
 
1.214 (1.201, 1.226) 
1 
Depression diagnosis at index visit 
     Major depression 
     Minor depression      
 
0.978 (0.969, 0.987) 
1
 
1.363 (1.349, 1.377) 
1 
Past treatment history 
     Newly-diagnosed depression 
 
     Non-newly-diagnosed depression with history of 
both AD treatment and depression diagnosis 
 
     Non-newly-diagnosed depression with history of 
either AD treatment or depression diagnosis  
 
1.110 (1.100, 1.121) 
 
1.076 (1.060, 1.093) 
 
 
1 
 
0.696 (0.689, 0.704) 
 
1.359 (1.334, 1.385) 
 
 
1 
 
Index AD treatment 
     SNRI 
     Other newer AD 
     TCA 
     Other older AD 
     Flupentixol/melitracen 
     Use of multiple ADs 
     SSRI 
 
0.995 (0.979, 1.011) 
1.014 (0.988, 1.040) 
1.046 (1.029, 1.063) 
1.063 (1.051, 1.076) 
1.031 (1.011, 1.052) 
1.070 (1.054, 1.086) 
1 
 
1.396 (1.372, 1.421) 
1.323 (1.288, 1.360) 
0.709 (0.695, 0.723) 
0.841 (0.829, 0.853) 
0.681 (0.664, 0.699) 
1.434 (1.409, 1.458) 
1 
Baseline physical illnesses   
 22 
  Cardiovascular disease 
     Yes vs. No 
  Diabetes mellitus 
      Yes vs. No 
  Chronic obstructive pulmonary disease 
      Yes vs. No 
  Renal disease 
      Yes vs. No 
  Cancer 
      Yes vs. No  
 
1.252 (1.238, 1.266) 
 
1.362 (1.343, 1.382) 
 
1.168 (1.153, 1.182) 
 
1.245 (1.220, 1.270) 
 
1.562 (1.528, 1.597) 
 
1.015 (1.002, 1.029) 
 
0.991 (0.974, 1.009) 
 
1.004 (0.990, 1.019) 
 
0.855 (0.835, 0.876) 
 
0.857 (0.835, 0.880) 
Baseline painful physical symptoms 
   Musculoskeletal 
      Yes vs. No 
   Back 
      Yes vs. No 
   Gastrointestinal 
      Yes vs. No 
   Headache/migraine/dizziness 
      Yes vs. No 
 
 
1.132 (1.121, 1.143) 
 
1.120 (1.109, 1.131) 
 
1.163 (1.153, 1.174) 
 
1.088 (1.078, 1.098) 
 
 
0.974 (0.963, 0.984) 
 
0.971 (0.960, 0.982) 
 
0.955 (0.945, 0.965) 
 
1.033 (1.022, 1.044) 
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Baseline mental illnesses 
   Schizophrenia 
      Yes vs. No 
   Other psychotic disorder 
      Yes vs. No 
   Substance related 
      Yes vs. No 
   Alcohol related 
      Yes vs. No 
   Drugs related 
      Yes vs. No 
   Bipolar spectrum disorder 
      Yes vs. No    
   Dementia 
      Yes vs. No 
   Generalized anxiety disorder 
      Yes vs. No 
   Obsessive-compulsive disorder 
      Yes vs. No 
   Panic disorder 
      Yes vs. No 
   Post-traumatic stress disorder 
      Yes vs. No 
 
 
0.892 (0.871, 0.931) 
 
0.966 (0.937, 0.996) 
 
1.335 (1.298, 1.372) 
 
1.467 (1.395, 1.544) 
 
1.196 (1.124, 1.273) 
 
0.991 (0.958, 1.024) 
 
1.291 (1.260, 1.323) 
 
1.007 (0.988, 1.026) 
 
0.837 (0.809, 0.865) 
 
0.902 (0.881, 0.924) 
 
1.045 (0.946, 1.154) 
 
 
3.443 (3.358, 3.531) 
 
1.514 (1.465, 1.565) 
 
1.323 (1.282, 1.364) 
 
1.707 (1.614, 1.805) 
 
1.208 (1.129, 1.292) 
 
1.649 (1.590, 1.709) 
 
1.451 (1.407, 1.496) 
 
1.016 (0.994, 1.038) 
 
1.241 (1.197, 1.286) 
 
1.062 (1.034, 1.090) 
 
1.229 (1.104, 1.368) 
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Total 12-month costs prior to index date (1000 USD) 1.200 (1.197, 1.203) 1.078 (1.074, 1.082) 
RR=relative risk; CI=confidence interval; AD=antidepressant; SNRI=serotonin norepinephrine reuptake inhibitor; TCA=tricyclic antidepressant; SSRI=selective 
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other older AD: maprotiline, moclobemide, and trazodone. 
 
Table 5. Multivariate logistic analysis for use of psychiatric inpatient and emergency services over the 12-month study period, overall sample 
 OR (95% CI) 
 Use of psychiatric inpatient 
services 
Use of psychiatric 
emergency services 
Age 0.974 (0.972, 0.975) 0.949 (0.947, 0.952) 
Sex 
Male 
 Female 
 
1.689 (1.620, 1.762) 
1 
 
1.731 (1.613, 1.858) 
1 
Depression diagnosis at index visit 
     Major depression 
     Minor depression      
 
1.909 (1.830, 1.991) 
1
 
1.771 (1.650, 1.901) 
1 
Past treatment history 
     Newly-diagnosed depression 
 
     Non-newly-diagnosed depression with history of 
both AD treatment and depression diagnosis 
 
     Non-newly-diagnosed depression with history of 
 
1.093 (1.042, 1.147) 
 
2.445 (2.310, 2.588) 
 
 
1 
 
1.022 (0.943, 1.108) 
 
1.593 (1.441, 1.762) 
 
 
1 
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either AD treatment or depression diagnosis  
Index AD treatment 
     SNRI 
     Other newer AD 
     TCA 
     Other older AD 
     Flupentixol/melitracen 
     Use of multiple ADs 
     SSRI 
 
1.385 (1.295, 1.481) 
1.712 (1.558, 1.880) 
0.747 (0.680, 0.820) 
0.926 (0.872, 0.984) 
0.601 (0.525, 0.688) 
1.454 (1.365, 1.549) 
1 
 
0.736 (0.642, 0.843) 
1.007 (0.838, 1.209) 
0.831 (0.708, 0.974) 
1.169 (1.062, 1.287) 
1.300 (1.097, 1.540) 
1.388 (1.250, 1.543) 
1 
Baseline physical illnesses 
  Cardiovascular disease 
     Yes vs. No  
  Chronic obstructive pulmonary disease 
      Yes vs. No 
  Renal disease 
      Yes vs. No 
  Cancer 
      Yes vs. No  
 
 
1.060 (1.003, 1.120) 
 
1.080 (1.017, 1.147) 
 
0.741 (0.667, 0.824) 
 
0.773 (0.685, 0.873) 
 
 
1.292 (1.178, 1.417) 
 
1.120 (1.010, 1.241) 
 
-- 
 
-- 
Baseline painful physical symptoms   
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   Headache/migraine/dizziness 
                                                    
Yes vs. No 
 
1.062 (1.016, 1.109) 
 
1.125 (1.046, 1.211) 
Baseline mental illnesses 
   Schizophrenia 
      Yes vs. No 
   Other psychotic disorder 
      Yes vs. No 
   Substance related 
      Yes vs. No 
   Alcohol related 
      Yes vs. No 
   Drugs related 
      Yes vs. No 
   Bipolar spectrum disorder 
      Yes vs. No    
   Dementia 
      Yes vs. No 
   Generalized anxiety disorder 
      Yes vs. No 
   Obsessive-compulsive disorder 
      Yes vs. No 
   Panic disorder 
 
 
4.271 (4.010, 4.548) 
 
1.776 (1.616, 1.953) 
 
2.277 (2.099, 2.471) 
 
3.526 (3.112, 3.995) 
 
1.257 (1.051, 1.502) 
 
2.453 (2.236, 2.691) 
 
1.817 (1.638, 2.015) 
 
0.840 (0.759, 0.929) 
 
0.864 (0.757, 0.987) 
 
 
 
2.971 (2.688, 3.283) 
 
1.594 (1.374, 1.848) 
 
1.982 (1.742, 2.255) 
 
2.014 (1.656, 2.449) 
 
1.328 (1.038, 1.699) 
 
2.655 (2.321, 3.037) 
 
1.440 (1.172, 1.770) 
 
-- 
 
1.278 (1.068, 1.529) 
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      Yes vs. No 0.825 (0.736, 0.924) 1.478 (1.271, 1.718) 
Total 12-month costs prior to index date (1000 USD) 1.059 (1.052, 1.067) 1.033 (1.021, 1.045) 
OR=odds ratio; CI=confidence interval; AD=antidepressant; SNRI=serotonin norepinephrine reuptake inhibitor; TCA=tricyclic antidepressant; SSRI=selective 
serotonin reuptake inhibitor; other newer AD: bupropion and mirtazapine; other older AD: maprotiline, moclobemide, and trazodone. 
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